摘要
目的:探讨早发型子痫前期抗凝治疗的临床效果及安全性。方法:将早发型子痫前期患者29例随机分为3组:A组10例,给予常规治疗;B组10例,在常规治疗的基础上加用低分子肝素治疗;C组9例,加用丹参治疗。观察3组患者临床指标的变化。结果:3组患者纳入研究时,临床指标无差异(P>0.05)。经治疗,B、C两组的临床疗效评分显著高于A组(14.2±2.1、12.9±2.8、9.5±3.9),P<0.05,期待治疗时间显著延长〔(18.2±7.2)天,(14.0±4.6)天、(10.1±3.4)天〕,P<0.05,纤维蛋白原(Fbg)及D-二聚体(D-D)显著降低。B组的新生儿体重及Apgar评分显著高于A组,而C组与A组相比差异无统计学意义。3组产后出血量无明显差异。结论:抗凝治疗有助于提高早发型子痫前期孕妇的治疗效果,对母儿安全。
Objective：To evaluate the effectiveness and safety of anti-coagulant therapies on patients with early-onset preeclampsia.Methods：Twenty-nine women with early-onset preeclampsia were divided into three groups randomly：group A （10 patients who received the routine therapies） and group B （10 patients who received low molecular weight heparin combined with routine therapies） and group C （9 patients who received Dansen combined with routine therapies）.Then the patients＇clinical changes were observed.Results：The conditions of the women in the three groups had no statistically difference when they were arranged to the study.Compared with group A,the results of group B and C were much better （scored 14.2 ± 2.1,12.9 ± 2.8 vs 9.5 ± 3.9）,P 0.05,periods of expectant management were much longer 〔（18.2 ± 7.2） d,（14.0 ± 4.6） d vs （10.1 ± 3.4） d〕,fibrinogen （Fbg） and D-dimmer （D-D） were lower after the treatment.Furthermore,patients in group B had higher birth weight and Apgar score than group A.There was no statistically difference between the group A and C of birth weight and Apgar score.While there was no notable difference in postpartum hemorrhage between the three groups.Conclusion：Anti-coagulant agents have some clinical effects on early-onset preeclampsia women and they are safe for the mothers and their fetuses.
出处
《中国妇幼保健》
CAS
北大核心
2010年第28期4021-4023,共3页
Maternal and Child Health Care of China
关键词
早发型子痫前期
抗凝治疗
低分子肝素
丹参
Early-onset preeclampsia
Anti-coagulant
Low molecular weight heparin
Dansen
